Twinlab's Sales Plunge 37% Amidst Going Concern Doubts

TL;DR

**Twinlab is bleeding cash with sales plummeting, making it a high-risk bet that needs a miracle capital infusion to survive.**

AI Summary

Twinlab Consolidated Holdings, Inc. reported a total net loss of $2.68 million for the three months ended September 30, 2024, a significant improvement from the $5.36 million net loss in the same period of 2023. However, net sales for the quarter decreased by 36.9% to $2.32 million from $3.68 million year-over-year. For the nine months ended September 30, 2024, the total net loss was $6.35 million, down from $12.17 million in 2023, while net sales fell to $8.21 million from $10.47 million. The company continues to face substantial doubt about its ability to continue as a going concern, evidenced by an accumulated deficit of $376.49 million and a working capital deficiency of $146.56 million as of September 30, 2024. Management is addressing these issues by focusing on core business growth, major customers, and negotiating lower supplier prices, but acknowledges the need to raise additional capital through debt, equity, or asset sales.

Why It Matters

Twinlab's continued operating losses and significant debt raise serious red flags for investors, indicating a high risk of financial distress or even bankruptcy. The substantial decline in net sales, down 36.9% year-over-year for the quarter, suggests a weakening competitive position in the nutritional supplements market. Employees face job insecurity given the company's precarious financial state and the abandonment of the NutraScience Labs (NSL) operations. Customers might experience disruptions in product availability or quality if the company's financial woes persist, while the broader market could see increased consolidation in the health and natural products sector if Twinlab struggles to compete.

Risk Assessment

Risk Level: high — The company has an accumulated deficit of $376.49 million and a working capital deficiency of $146.56 million as of September 30, 2024, indicating severe financial instability. Furthermore, $92.998 million of its debt is classified as current liabilities, highlighting immediate repayment pressures. These conditions, explicitly stated in the 'Going Concern' section, raise substantial doubt about its ability to continue operations.

Analyst Insight

Investors should avoid TWINLAB CONSOLIDATED HOLDINGS, INC. given the severe going concern risks, declining sales, and substantial debt. Current shareholders should consider divesting, as the company's need for additional capital on uncertain terms presents significant dilution risk or potential for further value erosion.

Financial Highlights

revenue

$2.32M

total Assets

$7.64M

total Debt

$153.02M

net Income

-$2.68M

eps

-$0.01

gross Margin

27.65%

cash Position

$14K

revenue Growth

-36.9%

Key Numbers

• $2.32M — Net Sales (Q3 2024) (Decreased 36.9% from $3.68M in Q3 2023)
• $2.68M — Total Net Loss (Q3 2024) (Improved from $5.36M loss in Q3 2023)
• $376.49M — Accumulated Deficit (As of September 30, 2024, indicating significant historical losses)
• $146.56M — Working Capital Deficiency (As of September 30, 2024, highlighting liquidity issues)
• $92.998M — Current Debt (Notes payable and current portion of long-term debt as of September 30, 2024)
• 259,092,833 — Common Shares Outstanding (As of October 16, 2025)
• $0.01 — Net Loss Per Share (Q3 2024) (Basic and diluted, improved from $0.02 in Q3 2023)

Key Players & Entities

• TWINLAB CONSOLIDATED HOLDINGS, INC. (company) — registrant
• NutraScience Labs (company) — discontinued operations
• SEC (regulator) — filing oversight
• $2.68 million (dollar_amount) — total net loss for Q3 2024
• $5.36 million (dollar_amount) — total net loss for Q3 2023
• $2.32 million (dollar_amount) — net sales for Q3 2024
• $3.68 million (dollar_amount) — net sales for Q3 2023
• $376.49 million (dollar_amount) — accumulated deficit as of September 30, 2024
• $146.56 million (dollar_amount) — working capital deficiency as of September 30, 2024
• $92.998 million (dollar_amount) — notes payable and current portion of long-term debt as of September 30, 2024

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to a significant accumulated deficit of $376.49 million and a working capital deficiency of $146.56 million as of September 30, 2024. Management's plans to raise capital through debt, equity, or asset sales are critical for continued operations.
• Declining Revenue [high — financial]: Net sales decreased by 36.9% to $2.32 million in Q3 2024 from $3.68 million in Q3 2023, and for the nine months ended September 30, 2024, sales fell to $8.21 million from $10.47 million year-over-year. This trend indicates a significant contraction in the company's core business.
• High Interest Expense [high — financial]: Interest expense, net, was $1.96 million for Q3 2024 and $5.92 million for the nine months ended September 30, 2024. This substantial expense burden contributes significantly to the net loss.
• Working Capital Deficiency [high — financial]: As of September 30, 2024, the company has a working capital deficiency of $146.56 million, with total current liabilities of $151.56 million exceeding total current assets of $4.99 million. This highlights immediate liquidity challenges.
• Inventory Management [medium — operational]: Inventories, net, decreased from $3.40 million at December 31, 2023, to $2.76 million at September 30, 2024. While this could indicate improved inventory management, it also reflects lower sales volume.
• Accumulated Deficit [high — financial]: The company's accumulated deficit stands at $376.49 million as of September 30, 2024, reflecting a long history of net losses and a substantial erosion of equity.

Industry Context

The nutritional supplement and wellness industry is highly competitive, with numerous players ranging from large established corporations to smaller niche brands. Trends include a growing consumer focus on health and wellness, demand for natural and organic ingredients, and increasing online sales channels. Companies like Twinlab face challenges in differentiating their products, managing supply chain costs, and navigating evolving regulatory landscapes.

Regulatory Implications

The company operates in the highly regulated dietary supplement industry. Compliance with FDA regulations regarding manufacturing practices (cGMP), labeling, and claims is paramount. Failure to adhere to these regulations can result in product recalls, warning letters, and significant financial penalties, impacting sales and reputation.

What Investors Should Do

1. Monitor management's progress in raising additional capital, as this is critical for the company's survival.
2. Analyze the sustainability of the reduced net loss in the context of declining sales and high interest expenses.
3. Evaluate the company's strategy for core business growth and its ability to secure favorable supplier pricing.
4. Assess the potential impact of continued going concern issues on future financing and operational capabilities.

Key Dates

• 2024-09-30: Quarter End — Reporting period for Q3 2024 financial results, showing a reduced net loss but declining sales and significant going concern issues.
• 2023-09-30: Quarter End — Prior year comparable period for Q3 2023 results, highlighting the year-over-year decline in net sales and a larger net loss.

Glossary

Accumulated deficit

The total cumulative net losses of a company that have not been offset by net income or other gains since its inception. (Indicates the company's long-term profitability issues, with a substantial deficit of $376.49 million as of September 30, 2024.)

Working capital deficiency

Occurs when a company's current liabilities exceed its current assets, indicating a potential inability to meet short-term obligations. (The company has a significant working capital deficiency of $146.56 million as of September 30, 2024, highlighting liquidity concerns.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The company faces substantial doubt about its ability to continue as a going concern, a critical warning for investors.)

Net sales

The total revenue generated from the sale of goods or services after deducting returns, allowances, and discounts. (Net sales declined by 36.9% in Q3 2024 to $2.32 million, indicating a significant drop in business activity.)

Cost of sales

The direct costs attributable to the production or purchase of the goods sold by a company. (Cost of sales decreased from $2.35 million in Q3 2023 to $1.68 million in Q3 2024, reflecting the lower sales volume.)

Gross profit

The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. (Gross profit fell from $1.33 million in Q3 2023 to $0.64 million in Q3 2024, directly impacted by the decrease in net sales.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Twinlab Consolidated Holdings, Inc. has significantly reduced its net loss from $5.36 million to $2.68 million. However, this improvement comes alongside a substantial 36.9% decrease in net sales, which fell to $2.32 million from $3.68 million. The company's financial position remains precarious, with a persistent working capital deficiency and substantial accumulated deficit, underscoring ongoing financial challenges despite the reduced loss.

Key Financial Figures

• $0 — er of shares of common stock, par value $0.001, outstanding on October 16, 2025 wa

Filing Documents

• tlcc-20240930.htm (10-Q) — 1464KB
• ex311_1.htm (EX-31.1) — 20KB
• ex321_2.htm (EX-32.1) — 7KB
• 0001753926-25-001621.txt ( ) — 7790KB
• tlcc-20240930_def.xml (EX-101.DEF) — 285KB
• tlcc-20240930_pre.xml (EX-101.PRE) — 446KB
• tlcc-20240930_cal.xml (EX-101.CAL) — 90KB
• tlcc-20240930_lab.xml (EX-101.LAB) — 759KB
• tlcc-20240930.xsd (EX-101.SCH) — 54KB
• tlcc-20240930_htm.xml (XML) — 1301KB

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "contemplate," "goals," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about our plans and ability to raise additional capital, including through equity offerings, debt financing, collaborations, strategic alliances, sales of assets, other merger and acquisition activities, or licensing arrangements; widespread health concerns; supply chain disruptions; the impact of inflation; consumer preferences; spending and debt levels; and the general economic and credit environment. These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. You should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets (Unaudited) 1 Condensed Consolidated Statements of Operations (Unaudited) 2 Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) 3 Condensed Consolidated Statements of Cash Flows (Unaudited) 4 Notes to Condensed Consolidated Financial Statements (Unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 25

– OTHER INFORMATION

PART II – OTHER INFORMATION 26 Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 27

– FINANCIAL INFORMATION

PART I. – FINANCIAL INFORMATION

. Financial Statements

Item 1 . Financial Statements Twinlab Consolidated Holdings, Inc. Condensed Consolidated Balance Sheets (unaudited) (amounts in thousands, except share and per share data) September 30, 2024 December 31, 2023 ASSETS Current assets: Cash $ 14 $ 19 Accounts receivable, net 1,843 1,911 Inventories, net 2,759 3,402 Prepaid expenses and other current assets 378 194 Current assets of discontinued operations - 161 Total current assets 4,994 5,687 Property and equipment, net 1 9 Right-of-use assets 1,239 1,889 Intangible assets, net 120 120 Other assets 1,290 1,290 Total assets $ 7,644 $ 8,995 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 2,890 $ 2,080 Lease liabilities 1,180 946 Accrued expenses and other current liabilities 2,632 2,052 Accrued interest 44,754 39,851 Notes payable and current portion of long-term debt 92,998 93,637 Current liabilities of discontinued operations 7,101 7,257 Total current liabilities 151,555 145,823 Long-term liabilities: Lease liabilities 1,463 2,197 Total long-term liabilities 1,463 2,197 Total liabilities 153,018 148,020 Stockholders' deficit: Preferred stock, $ 0.001 par value, 500,000,000 shares authorized, no shares issued and outstanding - - Common stock, $ 0.001 par value, 500,000,000 shares authorized, 393,898,884 and 393,898,884 shares issued, respectively 394 394 Additional paid-in capital 231,249 231,249 Stock subscriptions receivable ( 30 ) ( 30 ) Treasury stock, 134,806,051 shares at cost ( 500 ) ( 500 ) Accumulated deficit ( 376,487 ) ( 370,138 ) Total stockholders' deficit ( 145,374 ) ( 139,025 ) Total liabilities and stockholders' deficit $ 7,644 $ 8,995 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Twinlab Con

View Full Filing

View this 10-Q filing on SEC EDGAR